What does BrightPath Biotherapeutics Co., Ltd. do?
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product…
What is BrightPath Biotherapeutics Co., Ltd.'s P/E and P/B ratio?
BrightPath Biotherapeutics Co., Ltd. has a P/E ratio of -3.1 and a P/B ratio of 3.12.
What is BrightPath Biotherapeutics Co., Ltd.'s debt-to-equity ratio?
BrightPath Biotherapeutics Co., Ltd. has a debt-to-equity ratio of 0.00.
How much does BrightPath Biotherapeutics Co., Ltd. owe compared with what it owns?
BrightPath Biotherapeutics Co., Ltd. owes ¥0.10 for every ¥1 it owns (balance sheet Jun 2026), which is low.
What is BrightPath Biotherapeutics Co., Ltd.'s Positivity rank?
BrightPath Biotherapeutics Co., Ltd. is ranked #7,794 of 10,750 companies globally and #3,316 of 3,683 in Japan on PositoAI, with a Positivity Score of 19,734.
Does BrightPath Biotherapeutics Co., Ltd. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for BrightPath Biotherapeutics Co., Ltd..
Where can I read the latest news about BrightPath Biotherapeutics Co., Ltd.?
Recent headlines about BrightPath Biotherapeutics Co., Ltd. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does BrightPath Biotherapeutics Co., Ltd. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of BrightPath Biotherapeutics Co., Ltd.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.